HEARTLAND FHIR candidate 0.3.0 — draft, experimental R4 4.0.1 reference. Prepared for technical review; not evidence of clinical validation or vendor interoperability.

• Narrative Content
• XML
• JSON
• TTL

: HEARTLAND Evidence Level

Draft as of 2026-09-29

Raw json | Download

{
  "resourceType" : "CodeSystem",
  "id" : "heartland-evidence-level",
  "language" : "en",
  "text" : {
    "status" : "generated",
    "div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p class=\"res-header-id\"><b>Generated Narrative: CodeSystem heartland-evidence-level</b></p><a name=\"heartland-evidence-level\"> </a><a name=\"hcheartland-evidence-level\"> </a><p>This case-sensitive code system <code>https://fhir.heartlandprotocol.org/CodeSystem/heartland-evidence-level</code> defines the following codes:</p><table class=\"codes\"><tr><td style=\"white-space:nowrap\"><b>Code</b></td><td><b>Display</b></td><td><b>Definition</b></td></tr><tr><td style=\"white-space:nowrap\">established<a name=\"heartland-evidence-level-established\"> </a></td><td>Established Evidence</td><td>Interventions with strong guideline support, such as SGLT2i for all HF phenotypes endorsed by the 2022 AHA/ACC/HFSA guideline.</td></tr><tr><td style=\"white-space:nowrap\">emerging<a name=\"heartland-evidence-level-emerging\"> </a></td><td>Emerging Evidence</td><td>Recent trial findings not yet fully incorporated into guidelines, such as finerenone for HFpEF based on the FINEARTS-HF trial.</td></tr><tr><td style=\"white-space:nowrap\">pragmatic<a name=\"heartland-evidence-level-pragmatic\"> </a></td><td>Pragmatic Heuristic</td><td>Tools developed for clinical utility without formal statistical validation, such as the HEARTLAND Risk Score itself.</td></tr></table></div>"
  },
  "url" : "https://fhir.heartlandprotocol.org/CodeSystem/heartland-evidence-level",
  "version" : "0.3.0",
  "name" : "HeartlandEvidenceLevel",
  "title" : "HEARTLAND Evidence Level",
  "status" : "draft",
  "experimental" : true,
  "date" : "2026-09-29T19:00:36-04:00",
  "publisher" : "Vicky Muller Ferreira, MD",
  "contact" : [
    {
      "name" : "Vicky Muller Ferreira, MD",
      "telecom" : [
        {
          "system" : "url",
          "value" : "https://heartlandprotocol.org"
        },
        {
          "system" : "email",
          "value" : "vickymuller@heartlandprotocol.org"
        }
      ]
    },
    {
      "name" : "Vicky Muller Ferreira, MD",
      "telecom" : [
        {
          "system" : "email",
          "value" : "vickymuller@heartlandprotocol.org",
          "use" : "work"
        },
        {
          "system" : "url",
          "value" : "https://heartlandprotocol.org"
        }
      ]
    }
  ],
  "description" : "Three-tiered transparency labels distinguishing evidence strength behind HEARTLAND Protocol v3.2 recommendations, helping clinicians calibrate clinical decisions.",
  "jurisdiction" : [
    {
      "coding" : [
        {
          "system" : "urn:iso:std:iso:3166",
          "code" : "US"
        }
      ]
    }
  ],
  "copyright" : "CC-BY 4.0",
  "caseSensitive" : true,
  "content" : "complete",
  "count" : 3,
  "concept" : [
    {
      "code" : "established",
      "display" : "Established Evidence",
      "definition" : "Interventions with strong guideline support, such as SGLT2i for all HF phenotypes endorsed by the 2022 AHA/ACC/HFSA guideline."
    },
    {
      "code" : "emerging",
      "display" : "Emerging Evidence",
      "definition" : "Recent trial findings not yet fully incorporated into guidelines, such as finerenone for HFpEF based on the FINEARTS-HF trial."
    },
    {
      "code" : "pragmatic",
      "display" : "Pragmatic Heuristic",
      "definition" : "Tools developed for clinical utility without formal statistical validation, such as the HEARTLAND Risk Score itself."
    }
  ]
}